FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Gland Pharma IPO is a book built issue of Rs 6,479.55 crores. The issue is a combination of fresh issue of 0.83 crore shares aggregating to Rs 1,250.00 crores and offer for sale of 3.49 crore shares aggregating to Rs 5,229.55 crores.
Gland Pharma IPO bidding started from November 9, 2020 and ended on November 11, 2020. The allotment for Gland Pharma IPO was finalized on Tuesday, November 17, 2020. The shares got listed on BSE, NSE on November 20, 2020.
Gland Pharma IPO price band is set at ₹1490 to ₹1500 per share. The minimum lot size for an application is 10 Shares. The minimum amount of investment required by retail investors is ₹15,000.
Citigroup Global Markets India Private Limited, Haitong Securities India Private Limited, Kotak Mahindra Capital Company Limited and Nomura Financial Advisory And Securities (India) Pvt Ltd are the book running lead managers of the Gland Pharma IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Gland Pharma IPO RHP for detailed information.
| IPO Date | November 9, 2020 to November 11, 2020 |
| Listing Date | November 20, 2020 |
| Face Value | ₹1 per share |
| Price Band | ₹1490 to ₹1500 per share |
| Lot Size | 10 Shares |
| Total Issue Size | 43,196,968 shares (aggregating up to ₹6,479.55 Cr) |
| Fresh Issue | 8,333,333 shares (aggregating up to ₹1,250.00 Cr) |
| Offer for Sale | 34,863,635 shares of ₹1 (aggregating up to ₹5,229.55 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Gland Pharma IPO a total of 30,237,879 shares are offered. QIB: 8,639,394 (28.57%), RII: 15,118,939 (50.00%), NII: 6,479,546 (21.43%).
| Anchor Investor Shares Offered | - |
| QIB Shares Offered | 8,639,394 (28.57%) |
| NII (HNI) Shares Offered | 6,479,546 (21.43%) |
| Retail Shares Offered | 15,118,939 (50.00%) |
| Total Shares Offered | 30,237,879 (100%) |
Gland Pharma IPO opens on November 9, 2020, and closes on November 11, 2020.
| IPO Open Date | Monday, November 9, 2020 |
| IPO Close Date | Wednesday, November 11, 2020 |
| Basis of Allotment | Tuesday, November 17, 2020 |
| Initiation of Refunds | Wednesday, November 18, 2020 |
| Credit of Shares to Demat | Thursday, November 19, 2020 |
| Listing Date | Friday, November 20, 2020 |
| Cut-off time for UPI mandate confirmation | 5 PM on November 11, 2020 |
Investors can bid for a minimum of 10 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹195,000 |
| Lot Size Calculator | |||
Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters.
| Share Holding Pre Issue | 74% |
| Share Holding Post Issue | 58% |
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
| Particulars | For the year/period ended (Rs in million) | |||
|---|---|---|---|---|
| 30-June-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 46,912.65 | 40,860.39 | 35,235.49 | 29,294.68 |
| Total Revenue | 9,162.89 | 27,724.08 | 21,297.67 | 16,716.82 |
| Profit After Tax | 3,135.90 | 7,728.58 | 4,518.56 | 3,210.51 |
The net proceeds from the IPO will be used for the following purposes:
[Dilip Davda] No doubt that currently, the pharma sector is attracting investors following COVID-19 pandemic and the search of remedies for it globally. This company has posted good performance for the last three fiscals and spectacular numbers for Q1 of FY21, but will it sustain going forward is a major concern in the present context of negative sentiment for China connections globally. Based on P/BV and P/E parameters, the issue appears fully priced. Considering all these, though it sounds lucrative bet for the long term, risk savvy, cash surplus investors may consider investment at their own risk in this China connected IPO. Read detail review...
The Gland Pharma IPO is subscribed 2.06 times on Nov 11, 2020 6:00:01 PM. The public issue subscribed 0.24 times in the retail category, 6.40 times in the QIB category, and 0.51 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 6.40 |
| NII | 0.51 |
| Retail | 0.24 |
| Total | 2.06 |
Related Articles
| Listing Date | November 20, 2020 |
| BSE Script Code | 543245 |
| NSE Symbol | GLAND |
| ISIN | INE068V01023 |
| Final Issue Price | ₹1500 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹1,500.00 |
| ₹1,701.00 |
| ₹1,701.00 |
| ₹1,850.00 |
| ₹1,820.45 |
| NSE |
|---|
| ₹1,500.00 |
| ₹1,710.00 |
| ₹1,700.00 |
| ₹1,850.00 |
| ₹1,819.55 |
Gland Pharma Limited
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma 'X' Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. The issue is priced at ₹1490 to ₹1500 per share. The minimum order quantity is 10 Shares.
The IPO opens on November 9, 2020, and closes on November 11, 2020.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gland Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Gland Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gland Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gland Pharma IPO opens on November 9, 2020 and closes on November 11, 2020.
Gland Pharma IPO lot size is 10 Shares, and the minimum amount required is ₹15,000.
You can apply in Gland Pharma IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Gland Pharma IPO will be done on Tuesday, November 17, 2020, and the allotted shares will be credited to your demat account by Thursday, November 19, 2020. Check the Gland Pharma IPO allotment status.
Ashish Khater
Ashish Khater
Useful Articles
FREE Account Opening (₹0)
FREE Intraday Trading (Eq, F&O)
|
|
RHP
IPO Guru (1800+ Posts, 1600+ Likes)
Top Contributor (200+ Posts, 100+ Likes)
IPO Mentor (900+ Posts, 1700+ Likes)
